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Although sarcopenia (muscle loss) is associated with increased mortality after liver transplantation, its influence on other com-
plications is less well understood. We examined the association between sarcopenia and the risk of severe posttransplant
infections among adult liver transplant recipients. By calculating the total psoas area (TPA) on preoperative computed tomog-
raphy scans, we assessed sarcopenia among 207 liver transplant recipients. The presence or absence of a severe posttrans-
plant infection was determined by a review of the medical chart. The influence of posttransplant infections on overall survival
was also assessed. We identified 196 episodes of severe infections among 111 patients. Fifty-six patients had more than 1
infection. The median time to the development of an infection was 27 days (interquartile range513-62 days). When the
patients were grouped by TPA tertiles, patients in the lowest tertile had a greater than 4-fold higher chance of developing a
severe infection in comparison with patients in the highest tertile (odds ratio5 4.6, 95% confidence interval5 2.25-9.53). In a
multivariate analysis, recipient age (hazard ratio5 1.04, P5 0.02), pretransplant TPA (hazard ratio50.38, P< 0.01), and pre-
transplant total bilirubin level (hazard ratio5 1.05, P50.02) were independently associated with the risk of developing severe
infections. Patients with severe posttransplant infections had worse 1-year survival than patients without infections (76% versus
92%, P5 0.003). In conclusion, among patients undergoing liver transplantation, a lower TPA was associated with a height-
ened risk for posttransplant infectious complications and mortality. Future efforts should focus on approaches for assessing
and mitigating vulnerability in patients undergoing transplantation. Liver Transpl 19:1396-1402, 2013. VC 2013 AASLD.
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Liver transplants are costly and highly morbid proce-
dures. With increased efforts at providing efficient
and effective care, much attention has been given to
identifying patients who require more intense
resource utilization during the perioperative period.
One such group of patients is the medically frail.1-4
Although often considered a normal facet of aging,
this heightened state of vulnerability (known as
frailty) plays a role in susceptibility to a wide range
of illnesses, including infections.5,6 Although there
are many proposed ways for establishing the pres-
ence or absence of frailty, sarcopenia (muscle loss)
has gained attention recently because of its reprodu-
cibility and its demonstrated link with increased
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mortality and morbidity risk across diverse patient
groups.7-10
Although the influence of sarcopenia on the overall
health of older adults has been well recognized, the
potential impact of frailty on surgical outcomes has
only recently generated interest. Sarcopenia has been
used to evaluate perioperative risk across several
patient populations. Sarcopenic patients appear to be
at increased risk for major postoperative complica-
tions and death after a variety of surgical procedures,
including liver transplantation.11-14
Previously, we described the relationship between
sarcopenia and post–liver transplant survival.15
Although we observed a robust association between
sarcopenia and increased mortality, other clinical out-
comes of interest were not considered. An improved
understanding of the influence of sarcopenia on post-
transplant risk can inform the development of better
management strategies for this vulnerable population.
In that context, we examined the relationship between
sarcopenia and infectious complications after liver
transplantation.
PATIENTS AND METHODS
Setting and Study Population
The University of Michigan Health System (UMHS) is
a 931-bed, tertiary care medical center with an active
liver transplantation program. The UMHS liver trans-
plant program began in 1985 and now performs both
pediatric and adult liver transplants. Our study popu-
lation included all adult patients who underwent liver
transplantation between June 2002 and August 2008
and also underwent a preoperative abdominal/pelvic
computed tomography (CT) scan during the 90 days
before transplantation.
Outcomes
The development of severe infections (primarily health
care–associated and opportunistic infections) within
180 days of transplantation was the primary outcome
of interest. The presence or absence of infections and
associated organisms was determined by a review of
each recipient’s medical records. We defined severe
infections as infections requiring hospitalization or
intravenous or prolonged courses of antimicrobials or
infections resulting in persistent disability or death.
We focused on severe infections because more minor
infections (eg, mild cellulitis and uncomplicated uri-
nary tract infections) are generally of limited clinical
consequence. We defined health care–associated infec-
tions and opportunistic infections with established
Centers for Disease Control and Prevention/National
Healthcare Safety Network and American Society of
Transplantation criteria.16,17 From a practical stand-
point, minor infections are also nearly impossible to
ascertain in a retrospective manner. We recorded the
time to the diagnosis of infection and mortality as sec-
ondary outcomes.
Independent Variables
Our primary exposure of interest was sarcopenia,
which was measured with each patient’s total psoas
area (TPA). We computed each patient’s TPA from pre-
operative abdominal/pelvic CT scans as previously
described.15 In brief, we calculated the cross-sectional
area of both psoas muscles at the level of the fourth
lumbar vertebra via a standardized computer algo-
rithm. Other patient characteristics, including the
demographics, height, weight, body mass index (BMI),
indication for liver transplantation, preoperative labo-
ratory values, and presence of portal vein thrombosis,
were recorded. Preoperative laboratory values were
used to calculate the Model for End-Stage Liver Dis-
ease (MELD) scores for patients.
Statistical Analysis
To account for known sex influences on TPA in our
analysis, we first grouped patients into sex-stratified
TPA tertiles so that each tertile contained similar pro-
portions of men and women.9,18 We then compared
patient demographics, preoperative characteristics, and
preoperative laboratory values as well as donor charac-
teristics across TPA tertiles with 1-way analyses of var-
iance (for continuous variables) and Pearson chi-square
tests (for categorical variables). We included all trans-
plant indications when we were comparing indications
across TPA tertiles. Next, we compared patient demo-
graphics, characteristics, and laboratory values as well
as donor characteristics across groups by the presence
of severe posttransplant infections with unpaired t tests
for continuous variables and with Pearson chi-square
tests or Fisher’s exact test for categorical variables.
When we were comparing groups according to infec-
tions, we considered only a patient’s primary indication
for transplantation if he or she had multiple indications.
We further categorized primary transplant indications
into 1 of 3 categories [hepatocellular carcinoma (HCC)
without hepatitis C virus infection, hepatitis C virus,
and other] for bivariate analyses and further modeling.
To examine the relationship between TPA and post-
transplant severe infections, we first used logistic
regression to calculate the unadjusted odds ratio (OR)
for developing severe infections by the TPA tertile
level. We then entered all variables with P<0.2 in the
univariate analysis into a Cox proportional hazards
regression with backwards stepwise selection to iden-
tify independent risk factors for developing a severe
posttransplant infection. We examined risk factors for
developing bacterial, fungal, and viral infections with
the same method.
For the survival analysis, we calculated the days
from transplantation to death. We elected to censor
survival at the end of the study period or the last date
of follow-up, whichever occurred first. We estimated
survival functions with the Kaplan-Meier method and
stratified patients across the presence of severe infec-
tions. Finally, we compared survival curves and 1-
year survival rates between groups (infected or not
infected) with a log-rank test.
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We considered a 2-tailed P value<0.05 to be signifi-
cant. All statistical analyses were performed with SAS
9.2 (SAS Institute, Cary, NC). This study was
approved by the University of Michigan institutional
review board.
RESULTS
Patient Characteristics
Between June 2002 and August 2008, 509 adult
patients underwent liver transplantation at UMHS;
207 of these patients (40.7%) underwent abdominal
CT scanning within the 90 days before transplanta-
tion. These 207 patients formed our overall study
cohort. The mean age of the cohort was 51.769.8
years; 129 patients (62.3%) were male. The majority
of the patients (81.2%) were white. The most frequent
indications for transplantation were hepatitis C virus
(26.1%), HCC (25.1%), and alcoholic cirrhosis
(14.5%). Twenty one patients had more than 1 indica-
tion for transplantation.
Patient characteristics across TPA tertiles are pre-
sented in Table 1. Patients with high TPAs had a
higher mean BMI than patients with low TPAs (29.3
versus 26.5 kg/m2, P50.03), were more likely to have
a diagnosis of HCC (37.7% versus 14.5%, P50.01),
and had a lower mean MELD score (18.0 versus 22.7,
P<0.01; Table 1).
Table 2 shows differences between patients who
developed severe posttransplant infections and those
who did not. Infected patients had a higher mean
MELD score than patients who did not have a severe
infection (21.8 versus 17.4, P<0.01), a lower mean
albumin level (2.7 versus 2.9 g/dL, P50.04), and a
lower TPA (1762.4 versus 2116 mm2, P<0.01). In
addition, infected patients were less likely to have
HCC as an indication for transplantation (15.3% ver-
sus 36.5%, P<0.01; Table 2). Overall, patients with
severe posttransplant infections had a higher mortal-
ity rate (36.0%) than patients without infections
(18.8%, P<0.01).
Posttransplant Infections
We identified 196 severe infectious episodes among
111 patients. Fifty-six patients had more than 1
TABLE 1. Characteristics of Liver Transplant Recipients at UMHS From June 2002 to July 2008 With Preoperative CT
Scans Stratified by TPA Tertiles (n5207)
Characteristic Tertile 1 (n569) Tertile 2 (n569) Tertile 3 (n569) P Value
Age at transplant (years)* 52.069.8 52.0610.2 51.169.6 0.82
TPA: males (mm2)*† 1499.26309.9 2224.86157.8 2915.76381.5 <0.01
TPA: females (mm2)*† 954.36225.3 1423.16120.5 1978.86282.0 <0.01
Race [n (%)]
White 53 (76.8) 61 (88.4) 54 (78.3) 0.17
African American 5 (7.2) 7 (10.1) 11 (15.9) 0.30
Other 11 (15.9) 1 (1.4) 4 (5.8)
Preoperative BMI (kg/m2)* 26.565.6 27.566.4 29.366.3 0.03
Indication for transplantation [n (%)]‡
Hepatitis C virus 22 (31.9) 19 (27.5) 13 (18.8) 0.21
Hepatitis B virus 2 (2.9) 2 (2.9) 5 (7.2) 0.35
HCC 10 (14.5) 16 (23.2) 26 (37.7) 0.01
Alcoholic cirrhosis 11 (15.9) 11 (15.9) 8 (11.6) 0.70
Primary sclerosing cholangitis 6 (8.7) 5 (7.2) 10 (14.5) 0.33
Primary biliary cirrhosis 6 (8.7) 4 (5.8) 5 (7.2) 0.81
Autoimmune hepatitis 4 (5.8) 3 (4.3) 4 (5.8) 0.91
Nonalcoholic steatohepatitis 2 (2.9) 3 (4.3) 3 (4.3) 0.88
Fulminant hepatitis failure 1 (1.4) 2 (2.9) 1 (1.4) 0.78
Alpha-1 antitrypsin deficiency 1 (1.4) 2 (2.9) 0 0.36
Wilson’s disease 0 1 (1.4) 1 (1.4) 0.60
Other 9 (13.0) 6 (8.7) 4 (5.8) 0.33
Need for pretransplant dialysis [n (%)] 6 (8.7) 1 (1.4) 3 (4.3) 0.13
Preoperative laboratory values*
MELD score 22.767.9 18.768.2 18.066.2 <0.01
International normalized ratio 1.660.7 1.561.0 1.560.4 0.15
Creatinine (mg/dL) 1.9 61.3 1.360.9 1.260.7 <0.01
Total bilirubin (mg/dL) 4.2 4.0 3.2 0.44
Donor age (years)* 42.2618.0 36.6617.2 39.7615.6 0.17
*The data are presented as means and standard deviations.
†Measured at the fourth lumbar vertebra.
‡The n values refer to the total number of diagnoses. Twenty one patients had more than 1 indication for transplantation.
Hepatitis C virus–infected patients were divided by the presence and absence of HCC.
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infection. The median time to the first infectious epi-
sode was 27 days (interquartile range513-62 days);
53.1% of infections occurred within 30 days of trans-
plantation, and 73.9% occurred within 60 days of
transplantation.
The most common infectious episodes were blood-
stream infections (n548), intra-abdominal infections
(n565), and pneumonia (n514). In addition, there
were 15 opportunistic infections, the majority of
which (60.0%) were related to cytomegalovirus (CMV).
Details on the types of infections and associated
microorganisms are displayed in Table 3.
Risk Factors for Developing Severe
Posttransplant Infections
As shown in Table 4, a decreasing TPA (more sarcope-
nia) was associated with increased odds of developing
any infection [OR for tertile 1 versus tertile 354.6,
95% confidence interval (CI)52.25-9.53] or any bac-
terial infection (OR for tertile 1 versus tertile 355.2,
95% CI52.5-10.8; OR for tertile 2 versus tertile
352.5, 95% CI51.2-5.1). The results of a multivari-
ate Cox proportional hazards regression are presented
in Table 4. We identified the following variables as
independent risk factors for developing a serious
infection: recipient age (hazard ratio for developing
any infection51.04, P50.02), pretransplant TPA
(hazard ratio with an increasing TPA tertile50.38,
P<0.01), and pretransplant total bilirubin level (haz-
ard ratio51.05, P50.02; Table 5). Each of these fac-
tors remained statistically significant when infectious
episodes were stratified by the pathogen type (bacte-
rial, fungal, or viral).
Survival
Fifty-eight patients died during the study period.
Patients with severe infections had more than twice
the odds of posttransplant mortality than patients
without infections (OR52.4, 95% CI51.3-4.6).
Patients with any infection had a lower 1-year survival
rate than patients without infections [76% versus
92%, P50.003 (log-rank test)].
DISCUSSION
The need for evidence-based methods for reducing
perioperative risk among vulnerable populations
remains critical. This issue continues to garner much
attention from policymakers and medical leaders.19
Sarcopenia is a reproducible marker of vulnerability
and is closely linked to increased mortality and mor-
bidity risk across diverse patient and procedure
groups. The preceding results suggest that pretrans-
plant sarcopenia, measured by TPA, was associated
with an increased risk of serious posttransplant infec-
tions among a cohort of patients undergoing liver
TABLE 2. Characteristics of Liver Transplant Recipients With Infections and Liver Transplant Recipients W
ithout Infections
Characteristic Infection (n5111) No Infection (n596) P Value
Age at transplant (years)* 52.368.8 50.9610.8 0.30
Male [n (%)] 64 (57.7) 65 (67.7) 0.14
Race [n (%)]
White 91 (82.0) 77 (80.2) 0.75
African American 11 (9.9) 12 (12.5) 0.66
Other 9 (8.1) 7 (7.3)
Indication for transplantation [n (%)]†
Hepatitis C virus without HCC 34 (30.6) 20 (20.8) 0.11
HCC 17 (15.3) 35 (36.5) <0.01
Other 60 (54.1) 41 (42.7) 0.10
Need for pretransplant dialysis [n (%)] 8 (7.2) 2 (2.1) 0.11
Preoperative laboratory values*
MELD score 21.8 67.8 17.466.9 <0.01
International normalized ratio 1.660.6 1.660.9 0.91
Creatinine (mg/dL) 1.7 61.2 1.260.7 <0.01
Total bilirubin (mg/dL) 7.668.5 4.966.6 <0.01
Serum albumin (g/dL) 2.760.6 2.960.7 0.04
BMI (kg/m2)* 28.065.7 27.566.7 0.56
TPA (mm2)*‡ 1762.46701 21166643.3 <0.01
Donor age (years)* 40.4617.2 38.4616.8 0.43
Portal vein thrombosis [n (%)] 3 (2.7) 7 (7.3) 0.35
Mortality [n (%)] 40 (36.0) 18 (18.8) <0.01
*The data are presented as means and standard deviations.
†The n values indicate the primary indications for transplantation as recorded in the patient charts. Patients with multiple
indications for transplantation were assigned a primary indication for the bivariate analysis.
‡Measured at the fourth lumbar vertebra.
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transplantation. In addition, we observed that
patients with severe posttransplant infections had
decreased survival in comparison with recipients
without infections.
This work adds to a growing body of literature high-
lighting the negative influence of sarcopenia on patient
outcomes. Previous research has suggested that frailty
in general and sarcopenia in particular are associated
with poor outcomes after strokes, hip fractures, and
both elective and cancer operations.4,11-13,20 Although
we used TPA to quantify sarcopenia, other frailty meas-
ures have demonstrated similar outcomes. For exam-
ple, Kaido et al.14 used bioelectrical impedance
analysis to assess sarcopenia in a cohort of 124 adult
patients undergoing living donor liver transplantation.
Their findings mirror our results; low skeletal muscle
mass was independently associated with posttrans-
plant mortality.
Our findings are novel in the demonstration of an
association between sarcopenia and an increased risk
TABLE 3. Microorganisms Associated With Severe Infections Among Patients Undergoing Liver Transplantation
Type of Infection n Type of Infection n
Bloodstream/central line–associated bloodstream infections (n548) Pneumonia (n514)
Staphylococcus aureus 5 Pseudomonas aeruginosa 4
Coagulase-negative Staphylococcus 6 Klebsiella oxytoca 1
Enterococcus faecalis 5 Candida glabrata 1
Vancomycin-resistant Enterococcus 6 Polymicrobial 2
Morganella morganii 1 No organism isolated 6
Pseudomonas aeruginosa 3 Urinary tract infections (n58)
Escherichia coli 3 Vancomycin-resistant Enterococcus 2
Klebsiella pneumoniae 2 Escherichia coli 2
Candida albicans 5 Klebsiella pneumoniae 2
Candida glabrata 5 Enterobacter species 1
Alpha-hemolytic Streptococcus 1 Polymicrobial 1
Streptococcus milleri 1 Colitis (n531)
Serratia maltophilia 1 Clostridium difficile 30
Polymicrobial 4 Klebsiella pneumonia 1
Intra-abdominal infections (n565) Opportunistic infections (n515)
Staphylococcus aureus 3 Epstein-Barr virus 1
Vancomycin-sensitive Enterococcus 6 CMV* 9
Vancomycin-resistant Enterococcus 14 Disseminated histoplasmosis 1
Alpha-hemolytic Streptococcus 1 Cryptococcus peritonitis 1
Pseudomonas aeruginosa 3 Cryptococcus fungemia 1
Klebsiella oxytoca 2 Aspergillus pneumonia 1
Klebsiella pneumoniae 2 Aspergillus osteomyelitis 1
Candida albicans 2 Other (n56)
Candida glabrata 3 St. Louis encephalitis virus 1
Polymicrobial 22 Cutaneous herpes simplex 2
No organism isolated 7 Herpes zoster 2
Surgical site infections (n59) Influenza A virus 1
Staphylococcus aureus 3
Escherichia coli 1
Enterobacter cloacae 1
Polymicrobial 2
No organism isolated 2
*CMV infections included CMV colitis (4), CMV hepatitis (1), and disseminated CMV infections (4).
TABLE 4. Unadjusted ORs for Developing Any Serious Infection After Liver Transplantation by TPA Tertiles
TPA Tertiles
ORs for Developing a Severe Infection After Transplantation*
Any Infection Bacterial Infection Fungal Infection Viral Infection
First versus third 4.6 (2.25-9.53) 5.2 (2.53-10.8) 2.8 (0.82-9.25) 0.70 (0.21-2.30)
Second versus third 1.9 (0.97-3.80) 2.5 (1.25-5.09) 1.5 (0.42-5.75) 0.70 (0.21-2.30)
*The ranges within parentheses are 95% CIs.
1400 KRELL ET AL. LIVER TRANSPLANTATION, December 2013
of infectious complications after liver transplantation.
Infectious complications are significant sources of
morbidity and mortality for liver transplant recipients;
the potential influence of sarcopenia on infection-
related outcomes deserves further investigation.21
Improving our understanding of how sarcopenia con-
tributes to an individual patient’s risk and subse-
quent outcomes will be fundamental to developing
effective countermeasures for risk reduction and
management.
Some investigators have suggested that preoperative
risk stratification for identifying patients with the
highest risk can help to inform patient conversations
and enact more intensive preoperative preparation,
which is sometimes called prehabilitation.22-25 Among
patients awaiting liver transplantation, this may not
be feasible because of the sporadic nature of organ
availability and the poor overall health of transplant
candidates. An alternative strategy may be to use
measures of frailty such as sarcopenia to preemptively
identify patients for more intensive postoperative
monitoring and care specifically related to infection.
Such measures might include the use of different
perioperative antimicrobial regimens or approaches to
infection prophylaxis, an early intensive care unit
transfer for sarcopenic patients who experience com-
plications, or extra vigilance in terms of removing
lines and devices as soon as possible. Further investi-
gations should help to clarify which management
strategies would be most efficacious for mitigating or
managing these patients’ increased morbidity and
mortality risk.
Our study has several important limitations. First,
we analyzed a relatively small cohort from a single
transplant center. Future studies should include
larger numbers of patients from multiple institutions
and use prospectively recorded data. In addition, we
assessed only liver transplant candidates who had
preoperative abdominal/pelvic CT scans, and this
could have resulted in a selection bias because
patients who had preoperative CT scans and patients
who did not may have been inherently different. As
such, our results may not apply to a broader popula-
tion of liver transplant recipients. We did not attempt
to investigate differences in microbiology or in sites of
infection across TPA levels or the potential effects of
antimicrobial treatment. Notably, all patients received
standard perioperative infection prophylaxis, which
consisted of ampicillin and sulbactam or vancomycin
and levofloxacin (in the setting of a penicillin allergy).
We also did not account for the potential impact of
pretransplant infections or more minor postoperative
infections. Other clinical factors such as immunosup-
pression regimens were also not considered, although
most patients, at least initially, received similar regi-
mens according to our standard protocol (which
includes steroid induction, tacrolimus, mycopheno-
late, and steroid maintenance followed by a reduction
in the steroid dose over approximately 3 months).
Finally, there was possibly an ascertainment bias for
infections that might have occurred outside UMHS
(and not been reported).
Although the association between sarcopenia, infec-
tion, and mortality was striking, we cannot infer causal-
ity from these results. Nonetheless, the mechanism is
biologically plausible, and this work lends additional
support to the importance of frailty to outcomes after
liver transplantation. Further work should examine other
potential mechanisms for increased mortality among sar-
copenic patients as well as factors that may have con-
founded these results. Finally, although sarcopenia is a
consistent marker of increased risk, it remains unclear
whether it can be mitigated or improved, especially in a
population as ill as our study cohort was.
Sarcopenia, measured by TPA, seems to provide a
convenient and relatively simple way of assessing a
patient’s physiological reserve, and it may identify
those at increased risk for posttransplant
TABLE 5. Multivariate Analysis of Preoperative Risk Factors Associated With the Development of a Severe Infection
After Liver Transplantation (n5207).
Variable
Hazard Ratios for Developing a Severe Infection After Transplantation*
Any Infection Bacterial Infection Fungal Infection Viral Infection
Age at transplantation (years) 1.04 (1.01-1.08)† 1.04 (1.01-1.08)† 1.04 (1.01-1.08)† 1.04 (1.01-1.08)†
BMI (kg/m2) 1.04 (0.99-1.08) 1.04 (0.99-1.08) 1.04 (1.00-1.09) 1.03 (0.99-1.08)
Pretransplant serum
creatinine (mg/dL)
0.84 (0.61-1.13) 0.83 (0.61-1.13) 0.86 (0.64-1.17) 0.88 (0.65-1.19)
Pretransplant total
bilirubin (mg/dL)
1.05 (1.01-1.10)† 1.05 (1.00-1.09)† 1.05 (1.00-1.09)† 1.05 (1.01-1.09)†
Preoperative TPA (mm2) 0.38 (0.23-0.65)† 0.38 † (0.23-0.65) 0.35 (0.21-0.59)† 0.34 (0.20-0.58)†
Preoperative MELD score 0.99 (0.93-1.05) 0.99 (0.94-1.05) 0.99 (0.94-1.05) 0.99 (0.94-1.05)
NOTE: The results are presented for all infections (any infections) and subsets (bacterial, fungal, and viral pathogens).
Details are provided in Table 3.
*The ranges within parentheses are 95% CIs.
†P<0.05.
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complications and mortality. Specifically, those
patients with smaller TPAs seem to be at higher risk
for developing severe infections. Besides larger con-
firmatory studies, there is a critical need to better
understand the best way to assess and mitigate vul-
nerability in this extremely high-risk patient
population.
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